Zacks: Analysts Anticipate Eli Lilly and Co (LLY) Will Post Earnings of $1.08 Per Share

Analysts expect that Eli Lilly and Co (NYSE:LLY) will post earnings per share of $1.08 for the current quarter, Zacks reports. Four analysts have provided estimates for Eli Lilly and’s earnings, with the lowest EPS estimate coming in at $1.06 and the highest estimate coming in at $1.11. Eli Lilly and posted earnings of $0.95 per share during the same quarter last year, which would suggest a positive year over year growth rate of 13.7%. The firm is expected to issue its next earnings report before the market opens on Wednesday, January 31st.

According to Zacks, analysts expect that Eli Lilly and will report full-year earnings of $4.22 per share for the current fiscal year, with EPS estimates ranging from $4.15 to $4.25. For the next financial year, analysts forecast that the firm will report earnings of $4.64 per share, with EPS estimates ranging from $4.58 to $4.77. Zacks Investment Research’s EPS calculations are a mean average based on a survey of research analysts that follow Eli Lilly and.

Eli Lilly and (NYSE:LLY) last posted its earnings results on Tuesday, October 24th. The company reported $1.05 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.03 by $0.02. Eli Lilly and had a return on equity of 30.27% and a net margin of 9.90%. The firm had revenue of $5.66 billion for the quarter, compared to analyst estimates of $5.52 billion. During the same quarter in the prior year, the company earned $0.88 EPS. Eli Lilly and’s revenue was up 9.0% on a year-over-year basis.

Several equities analysts recently issued reports on the company. Jefferies Group set a $100.00 target price on Eli Lilly and and gave the stock a “buy” rating in a research note on Tuesday. Goldman Sachs Group lowered Eli Lilly and from a “buy” rating to a “neutral” rating and increased their price target for the company from $86.98 to $95.00 in a research report on Tuesday. Argus raised Eli Lilly and from a “hold” rating to a “buy” rating and increased their price target for the company from $85.52 to $115.00 in a research report on Friday, January 5th. Credit Suisse Group reaffirmed a “hold” rating on shares of Eli Lilly and in a research report on Wednesday, December 13th. Finally, BMO Capital Markets set a $73.00 price target on Eli Lilly and and gave the company a “sell” rating in a research report on Tuesday, December 12th. Three equities research analysts have rated the stock with a sell rating, seven have given a hold rating and nine have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of $92.75.

In related news, major shareholder Lilly Endowment Inc sold 200,000 shares of the firm’s stock in a transaction that occurred on Wednesday, December 13th. The stock was sold at an average price of $88.20, for a total transaction of $17,640,000.00. Following the transaction, the insider now owns 123,084,104 shares in the company, valued at approximately $10,856,017,972.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, SVP Susan Mahony sold 36,585 shares of the firm’s stock in a transaction that occurred on Monday, December 4th. The stock was sold at an average price of $86.18, for a total value of $3,152,895.30. Following the transaction, the senior vice president now owns 54,885 shares in the company, valued at approximately $4,729,989.30. The disclosure for this sale can be found here. In the last quarter, insiders sold 251,088 shares of company stock worth $22,041,236. Company insiders own 0.20% of the company’s stock.

A number of large investors have recently added to or reduced their stakes in LLY. First Financial Bank Trust Division lifted its position in Eli Lilly and by 11.3% during the 2nd quarter. First Financial Bank Trust Division now owns 5,705 shares of the company’s stock worth $469,000 after acquiring an additional 578 shares during the period. Gateway Investment Advisers LLC lifted its position in Eli Lilly and by 3.0% during the 2nd quarter. Gateway Investment Advisers LLC now owns 570,790 shares of the company’s stock worth $46,976,000 after acquiring an additional 16,549 shares during the period. Pennsylvania Trust Co lifted its position in Eli Lilly and by 78.7% during the 2nd quarter. Pennsylvania Trust Co now owns 14,020 shares of the company’s stock worth $1,154,000 after acquiring an additional 6,175 shares during the period. Stokes & Hubbell Capital Management LLC acquired a new stake in Eli Lilly and during the 2nd quarter worth approximately $300,000. Finally, Beutel Goodman & Co Ltd. lifted its position in Eli Lilly and by 13.8% during the 2nd quarter. Beutel Goodman & Co Ltd. now owns 2,564,357 shares of the company’s stock worth $162,556,000 after acquiring an additional 311,417 shares during the period. Hedge funds and other institutional investors own 76.35% of the company’s stock.

Eli Lilly and (LLY) traded down $0.39 on Friday, reaching $85.82. The company had a trading volume of 4,445,800 shares, compared to its average volume of 3,173,292. Eli Lilly and has a 1 year low of $74.00 and a 1 year high of $89.09. The company has a current ratio of 1.38, a quick ratio of 1.03 and a debt-to-equity ratio of 0.66. The firm has a market cap of $94,440.00, a price-to-earnings ratio of 40.87, a price-to-earnings-growth ratio of 1.68 and a beta of 0.35.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 9th. Stockholders of record on Thursday, February 15th will be issued a $0.5625 dividend. The ex-dividend date of this dividend is Wednesday, February 14th. This represents a $2.25 dividend on an annualized basis and a dividend yield of 2.62%. This is an increase from Eli Lilly and’s previous quarterly dividend of $0.52. Eli Lilly and’s dividend payout ratio is presently 99.05%.

ILLEGAL ACTIVITY WARNING: This piece of content was published by American Banking News and is the sole property of of American Banking News. If you are accessing this piece of content on another site, it was illegally copied and reposted in violation of US & international copyright & trademark laws. The correct version of this piece of content can be viewed at https://www.americanbankingnews.com/2018/01/19/zacks-analysts-anticipate-eli-lilly-and-co-lly-will-post-earnings-of-1-08-per-share.html.

About Eli Lilly and

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Get a free copy of the Zacks research report on Eli Lilly and (LLY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply